EA201190011A1 - Пероральные лекарственные формы бендамустина - Google Patents

Пероральные лекарственные формы бендамустина

Info

Publication number
EA201190011A1
EA201190011A1 EA201190011A EA201190011A EA201190011A1 EA 201190011 A1 EA201190011 A1 EA 201190011A1 EA 201190011 A EA201190011 A EA 201190011A EA 201190011 A EA201190011 A EA 201190011A EA 201190011 A1 EA201190011 A1 EA 201190011A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
bendamustin
medicinal forms
oral medicinal
bendamustine
Prior art date
Application number
EA201190011A
Other languages
English (en)
Other versions
EA020354B1 (ru
Inventor
Джеффри Колледж
Маргарета Олтхофф
Original Assignee
Астеллас Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40588059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201190011(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астеллас Дойчланд Гмбх filed Critical Астеллас Дойчланд Гмбх
Publication of EA201190011A1 publication Critical patent/EA201190011A1/ru
Publication of EA020354B1 publication Critical patent/EA020354B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В настоящем изобретении предложена пероральная фармацевтическая композиция, содержащая бендамустин или его фармацевтически приемлемые сложный эфир, соль или сольват в качестве активного ингредиента и фармацевтически приемлемый эксципиент, который представляет собой фармацевтически приемлемое неионное поверхностно-активное вещество, выбранное из группы, состоящей из полиэтоксилированного касторового масла или его производного и блок-сополимера этиленоксида и пропиленоксида.
EA201190011A 2008-12-03 2009-12-03 Пероральные лекарственные формы бендамустина EA020354B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075915 2008-12-03
PCT/EP2009/008857 WO2010063493A1 (en) 2008-12-03 2009-12-03 Oral dosage forms of bendamustine

Publications (2)

Publication Number Publication Date
EA201190011A1 true EA201190011A1 (ru) 2012-02-28
EA020354B1 EA020354B1 (ru) 2014-10-30

Family

ID=40588059

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190011A EA020354B1 (ru) 2008-12-03 2009-12-03 Пероральные лекарственные формы бендамустина

Country Status (25)

Country Link
US (4) US20120003305A1 (ru)
EP (1) EP2367542B1 (ru)
JP (1) JP5778037B2 (ru)
KR (1) KR101688038B1 (ru)
CN (2) CN105363037B (ru)
AU (1) AU2009321745B2 (ru)
BR (1) BRPI0922806B8 (ru)
CA (1) CA2745525A1 (ru)
CO (1) CO6400183A2 (ru)
CY (1) CY1114977T1 (ru)
DK (1) DK2367542T3 (ru)
EA (1) EA020354B1 (ru)
ES (1) ES2451540T3 (ru)
HR (1) HRP20140204T1 (ru)
IL (1) IL213270A (ru)
MX (1) MX2011005643A (ru)
NZ (1) NZ592970A (ru)
PL (1) PL2367542T3 (ru)
PT (1) PT2367542E (ru)
RS (1) RS53201B (ru)
SI (1) SI2367542T1 (ru)
SM (1) SMT201400053B (ru)
UA (1) UA102120C2 (ru)
WO (1) WO2010063493A1 (ru)
ZA (1) ZA201103791B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
EP2575784B1 (en) * 2010-06-02 2018-08-08 Astellas Deutschland GmbH Oral dosage forms of bendamustine
CN102375044B (zh) * 2010-08-18 2015-04-08 重庆华邦胜凯制药有限公司 一种盐酸苯达莫司汀中间体z6有关物质的分析方法
WO2013046223A1 (en) * 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
EP4218937A3 (en) * 2011-10-31 2023-10-25 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
SI2656843T1 (sl) 2012-04-26 2015-06-30 Helmut Schickaneder Estri bendamustina in povezane spojine ter njihova medicinska uporaba
AU2013342015B2 (en) * 2012-11-12 2016-11-24 Ignyta, Inc. Bendamustine derivatives and methods of using same
EP2968153B1 (en) * 2013-03-12 2018-05-02 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
JP2016153374A (ja) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 炎症性疾患を治療又は予防するための医薬組成物
CN105491886B (zh) 2013-08-27 2019-01-29 V·沃道里斯 苯达莫司汀医药组合物
AU2018346395A1 (en) 2017-10-05 2020-04-30 Mecox Curemed Co., Ltd. Oral bendamustine formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132502A (en) * 1872-10-22 Improvement in machines for removing snow from railroads
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
CN101119708B (zh) * 2005-01-14 2014-12-24 赛福伦公司 苯达莫司汀冻干药物组合物
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN101028249A (zh) * 2007-04-12 2007-09-05 济南康泉医药科技有限公司 一种含新生血管抑制剂及烷化剂的抗癌组合物
CN101045058A (zh) * 2007-04-28 2007-10-03 济南帅华医药科技有限公司 一种含烷化剂及激素类药物的抗癌组合物
CN101084876A (zh) * 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
ES2451540T3 (es) 2014-03-27
US20120003305A1 (en) 2012-01-05
UA102120C2 (ru) 2013-06-10
EP2367542B1 (en) 2014-01-01
SMT201400053B (it) 2014-07-07
PL2367542T3 (pl) 2014-05-30
DK2367542T3 (da) 2014-03-10
AU2009321745B2 (en) 2016-06-23
EA020354B1 (ru) 2014-10-30
KR20110102393A (ko) 2011-09-16
MX2011005643A (es) 2011-09-27
US20150335588A1 (en) 2015-11-26
CY1114977T1 (el) 2016-12-14
AU2009321745A1 (en) 2011-06-23
ZA201103791B (en) 2012-07-25
JP2012510484A (ja) 2012-05-10
US10543196B2 (en) 2020-01-28
IL213270A0 (en) 2011-07-31
KR101688038B1 (ko) 2016-12-20
SI2367542T1 (sl) 2014-05-30
HRP20140204T1 (hr) 2014-04-11
CN105363037A (zh) 2016-03-02
PT2367542E (pt) 2014-03-10
CA2745525A1 (en) 2010-06-10
IL213270A (en) 2017-05-29
RS53201B (en) 2014-06-30
CN102281871A (zh) 2011-12-14
WO2010063493A1 (en) 2010-06-10
US20140018334A1 (en) 2014-01-16
CO6400183A2 (es) 2012-03-15
BRPI0922806A2 (pt) 2015-12-22
EP2367542A1 (en) 2011-09-28
BRPI0922806B1 (pt) 2020-03-03
CN105363037B (zh) 2019-02-05
NZ592970A (en) 2013-05-31
JP5778037B2 (ja) 2015-09-16
US20170095452A1 (en) 2017-04-06
BRPI0922806B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
EA201190011A1 (ru) Пероральные лекарственные формы бендамустина
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
EA201590674A1 (ru) Производные 5-фенокси-3h-пиримидин-4-она и их применение в качестве ингибиторов обратной транскрипазы вич
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
ATE536172T1 (de) Ezetimibzusammensetzungen
ECSP13012812A (es) Formulaciones inmunosupresoras
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
EA201290229A1 (ru) Производные спиролактама и их применение
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
EA201001125A1 (ru) Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид
TR201803451T4 (tr) Olmesartan formülasyonlari.
WO2011135582A3 (en) Pharmaceutical compositions of dronedarone
ECSP12012352A (es) Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal
WO2011128914A3 (en) Extended release pharmaceutical compositions of pramipexole
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування
UA109243U (uk) Тверда лікарська форма, що містить інгібітор віл протеази
AR082967A1 (es) Formulaciones de inhibidor de histona desacetilasa en combinacion con bendamustina y uso de las mismas, metodo de tratamiento
TR201006802A1 (tr) Prasugrelin oral yolla dağılan formülasyonları.
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos
RU2012148768A (ru) Фармацевтическая композиция на основе производного трииндолилметана в качестве противоопухолевого средства
UA105513C2 (ru) Лекарственная форма замедленного высвобождения глюкозамина